AnaptysBio, Inc. ANAB

Company Overview

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapeutics for inflammatory and immune-mediated diseases. The company operates within the biopharmaceutical and immunology sectors, with a primary emphasis on novel biologic drugs designed to modulate immune system pathways. Its core revenue model is currently research- and development-driven, with no commercialized products as of the most recent public filings, and funding primarily derived from equity financing, collaborations, and prior licensing agreements.

AnaptysBio’s strategic positioning centers on its proprietary antibody discovery and optimization technologies, which are designed to generate highly selective therapeutic antibodies. The company was founded in 2005 and initially focused on antibody engineering platforms before evolving into a product-driven biotechnology company with internally developed clinical assets. Over time, AnaptysBio transitioned from a platform-licensing model toward advancing wholly owned drug candidates through clinical development.